4-氨基-6-氯吲哚 | 431046-15-0

• 物质功能分类: 医药中间体 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-氨基-6-氯吲哚
• 英文名称: 6-chloro-1H-indol-4-amine
• CAS: 431046-15-0
• 化学式: C₈H₇ClN₂
• mdl: MFCD07781455
• 分子量: 166.61
• InChiKey: WQESCKJRCSIUGY-UHFFFAOYSA-N

物化性质

• 沸点：
  394℃
• 密度：
  1.435
• 闪点：
  192℃

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] AROMATIC HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AROMATIQUES ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2016004882A1

  公开（公告）日：2016-01-14

  Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.

  本文提供了用于治疗阿尔茨海默病的芳香杂环衍生物或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药用可接受盐或其前药。本文还提供了含有这些化合物的药物组合物，以及利用这些化合物或药物组合物管理或治疗5-HT6受体介导的疾病，特别是在制造用于管理或治疗阿尔茨海默病的药物的过程中。
• [EN] LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144702A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了一些LOXL2抑制剂化合物，制备这些化合物的方法，包括这些化合物的药物组合物和药物剂以及在治疗与LOXL2活性相关的疾病、疾病或紊乱的方法。
• Compounds useful in the treatment of cns disorders
  申请人：Bromidge Mark Steven

  公开号：US20050176705A1

  公开（公告）日：2005-08-11

  The invention relates to novel indole compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of various CNS disorders.

  本发明涉及具有药理活性的新型吲哚化合物，其制备过程，包含它们的组合物以及它们在治疗各种中枢神经系统疾病中的应用。
• Lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US10766860B2

  公开（公告）日：2020-09-08

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。
• Cyanoindoline derivatives as NIK inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US11186589B2

  公开（公告）日：2021-11-30

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及可用于哺乳动物治疗和/或预防的药物制剂，尤其涉及可用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病等疾病的NF-κB诱导激酶（NIK-又称MAP3K14）抑制剂。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物或药物组合物预防或治疗癌症、炎症性疾病、代谢紊乱（包括肥胖和糖尿病）和自身免疫性疾病等疾病。